$SNTI
Senti Biosciences, Inc. Stock $snti

$snti Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000185427024000029 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$2.561M
YoY Change	-100.0%	-100.0%	-40.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.522M	$9.305M	$37.18M
YoY Change	-23.26%	-14.73%	-8.99%
% of Gross Profit
Research & Development	$8.779M	$9.122M	$32.15M
YoY Change	-22.43%	-0.45%	-5.63%
% of Gross Profit
Depreciation & Amortization	$984.0K	$992.0K	$3.400M
YoY Change	96.8%	120.44%	143.2%
% of Gross Profit
Operating Expenses	$16.30M	$18.43M	$95.29M
YoY Change	-22.82%	-8.21%	27.19%
Operating Profit	-$16.30M		-$92.73M
YoY Change	-17.81%		31.29%
Interest Expense	$331.0K	$426.0K	$2.864M
YoY Change	-68.8%	-62.23%	68.37%
% of Operating Profit
Other Income/Expense, Net	$4.190M	-$416.0K	$9.321M
YoY Change	276.8%	-161.36%	-24.95%
Pretax Income	-$12.11M	-$18.69M	-$83.41M
YoY Change	-35.31%	2.62%	43.28%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$12.11M	-$71.06M	-$71.10M
YoY Change	-35.31%	290.21%	22.14%
Net Earnings / Revenue			-2776.26%
Basic Earnings Per Share	-$0.26		-$1.60
Diluted Earnings Per Share	-$0.26	-$0.42	-$1.60
COMMON SHARES
Basic Shares Outstanding	45.76M shares	44.55M shares	44.37M shares
Diluted Shares Outstanding	45.71M shares		44.37M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.72M	$35.93M	$35.93M
YoY Change	-68.83%	-63.55%	-63.55%
Cash & Equivalents	$23.70M	$35.93M	$35.93M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$0.00	$195.0K	$17.57M
YoY Change	-100.0%	93.07%	418.29%
Inventory
Prepaid Expenses	$2.628M	$2.546M
Receivables	$76.00K	$112.0K	$112.0K
Other Receivables	$17.85M	$17.59M	$17.59M
Total Short-Term Assets	$55.67M	$71.20M	$71.20M
YoY Change	-30.86%	-30.59%	-30.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.35M	$25.34M	$41.61M
YoY Change	-58.71%	-54.86%	-44.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$86.00K	$215.0K	$5.553M
YoY Change	-81.74%	-26.62%	51.76%
Total Long-Term Assets	$46.52M	$48.28M	$48.28M
YoY Change	-42.51%	-38.27%	-38.27%
TOTAL ASSETS
Total Short-Term Assets	$55.67M	$71.20M	$71.20M
Total Long-Term Assets	$46.52M	$48.28M	$48.28M
Total Assets	$102.2M	$119.5M	$119.5M
YoY Change	-36.7%	-33.91%	-33.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.624M	$1.250M	$1.250M
YoY Change	-37.1%	-44.86%	-44.86%
Accrued Expenses	$6.912M	$9.958M	$9.958M
YoY Change	-28.35%	-32.95%	-32.95%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$97.00K	$97.00K
YoY Change	5.26%
Total Short-Term Liabilities	$9.609M	$12.67M	$12.67M
YoY Change	-25.31%	-29.81%	-29.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$36.48M	$39.90M	$39.90M
YoY Change	0.93%	12.47%	12.47%
Total Long-Term Liabilities	$36.48M	$39.90M	$39.90M
YoY Change	0.73%	12.47%	12.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.609M	$12.67M	$12.67M
Total Long-Term Liabilities	$36.48M	$39.90M	$39.90M
Total Liabilities	$46.09M	$52.57M	$52.57M
YoY Change	-6.1%	-1.79%	-1.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$256.5M	-$244.3M
YoY Change	33.59%	40.98%
Common Stock	$5.000K	$5.000K
YoY Change	25.0%	25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$56.09M	$66.91M	$66.91M
YoY Change
Total Liabilities & Shareholders Equity	$102.2M	$119.5M	$119.5M
YoY Change	-36.7%	-33.91%	-33.91%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$12.11M	-$71.06M	-$71.10M
YoY Change	-35.31%	290.21%	22.14%
Depreciation, Depletion And Amortization	$984.0K	$992.0K	$3.400M
YoY Change	96.8%	120.44%	143.2%
Cash From Operating Activities	-$11.68M	-$7.037M	-$52.40M
YoY Change	-28.35%	-21.86%	50.15%
INVESTING ACTIVITIES
Capital Expenditures	$15.00K	$4.000K	$12.04M
YoY Change	-99.77%	-99.95%	-70.9%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$105.0K	$42.12M
YoY Change	-100.0%	-100.26%	-203.77%
Cash From Investing Activities	-$15.00K	$101.0K	$30.08M
YoY Change	-99.84%	-100.21%	-136.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$512.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	556.0K	$779.0K
YoY Change	-100.0%	-36.53%	-99.34%
NET CHANGE
Cash From Operating Activities	-$11.68M	-7.037M	-$52.40M
Cash From Investing Activities	-$15.00K	101.0K	$30.08M
Cash From Financing Activities	$0.00	556.0K	$779.0K
Net Change In Cash	-$11.70M	-6.380M	-$21.54M
YoY Change	-54.73%	-88.86%	-1369.99%
FREE CASH FLOW
Cash From Operating Activities	-$11.68M	-$7.037M	-$52.40M
Capital Expenditures	$15.00K	$4.000K	$12.04M
Free Cash Flow	-$11.70M	-$7.041M	-$64.43M
YoY Change	-48.72%	-59.86%	-15.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2437900
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Corporate Drive, First Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Trading Symbol TradingSymbol	SNTI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32150000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28145000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37176000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38225000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1701000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-207000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9461000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9321000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12419000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71059000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58209000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.60
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.60
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26110785	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26110785	shares
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001854270
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	P20D
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40440
CY2023	dei	Entity Registrant Name EntityRegistrantName	Senti Biosciences, Inc.
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	(650)
CY2023	dei	Local Phone Number LocalPhoneNumber	239-2030
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	23500000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45755021	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35926000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57621000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	40942000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	209000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	71200000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	102579000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3522000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3366000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1119000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25338000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51361000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16274000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18418000	usd
CY2023Q4	snti	Contingent Consideration Receivable ContingentConsiderationReceivable	1816000	usd
CY2022Q4	snti	Contingent Consideration Receivable ContingentConsiderationReceivable	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	215000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	283000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	4785000	usd
CY2023Q4	us-gaap	Assets Assets	119484000	usd
CY2022Q4	us-gaap	Assets Assets	180792000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1250000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1370000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	97000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	snti	Early Exercise Liability Current EarlyExerciseLiabilityCurrent	135000	usd
CY2022Q4	snti	Early Exercise Liability Current EarlyExerciseLiabilityCurrent	135000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	799000	usd
CY2023Q4	snti	Deferred Sublease Income DeferredSubleaseIncome	989000	usd
CY2022Q4	snti	Deferred Sublease Income DeferredSubleaseIncome	0	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5927000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12576000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4031000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1988000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	243000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1185000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12672000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18053000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33538000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35103000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	20000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	227000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	6331000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2023Q4	snti	Early Exercise Liability Noncurrent EarlyExerciseLiabilityNoncurrent	10000	usd
CY2022Q4	snti	Early Exercise Liability Noncurrent EarlyExerciseLiabilityNoncurrent	146000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	52571000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	53529000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45700161	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45700161	shares
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244344000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173286000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	66913000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	127263000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119484000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180792000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	25962000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	95288000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	66370000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-92727000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-62084000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2864000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	2323000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-83406000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-49665000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	12348000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-8545000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71058000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.88
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.88
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.90
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.90
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.28
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.33
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.33
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44372223	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44372223	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-111457000	usd
CY2022	snti	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	19517988	shares
CY2022	snti	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	171833000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	171835000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	111959000	usd
CY2022	snti	Adjustments To Additional Paid In Capital Contingent Consideration Liability On Closing Of The Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalContingentConsiderationLiabilityOnClosingOfTheReverseRecapitalization	9688000	usd
CY2022	snti	Stock Issued During Period Value Cancellation And Exchange Of Convertible Debt StockIssuedDuringPeriodValueCancellationAndExchangeOfConvertibleDebt	5184000	usd
CY2022	snti	Adjustments To Additional Paid In Capital Gain On Embedded Derivative AdjustmentsToAdditionalPaidInCapitalGainOnEmbeddedDerivative	-1289000	usd
CY2022	snti	Stock Issued During Period Value Purchase Agreement Fee Settled In Stock StockIssuedDuringPeriodValuePurchaseAgreementFeeSettledInStock	924000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	496000	usd
CY2022	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	965000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	151000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16392000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	127263000	usd
CY2023	snti	Stock Issued During Period Value Purchase Agreement Fee Settled In Stock StockIssuedDuringPeriodValuePurchaseAgreementFeeSettledInStock	528000	usd
CY2023	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	136000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	375000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9670000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71058000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2023	snti	Depreciation And Amortization Including Discontinued Operations DepreciationAndAmortizationIncludingDiscontinuedOperations	3561000	usd
CY2022	snti	Depreciation And Amortization Including Discontinued Operations DepreciationAndAmortizationIncludingDiscontinuedOperations	1398000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1868000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2522000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1069000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	356000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	21862000	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-207000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9461000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	25962000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9670000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16392000	usd
CY2023	snti	Stock Issued For Purchase Agreement Fee StockIssuedForPurchaseAgreementFee	0	usd
CY2022	snti	Stock Issued For Purchase Agreement Fee StockIssuedForPurchaseAgreementFee	196000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	35000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	8000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-290000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	186000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	716000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2055000	usd
CY2023	snti	Increase Decrease In Deferred Sublease Income IncreaseDecreaseInDeferredSubleaseIncome	689000	usd
CY2022	snti	Increase Decrease In Deferred Sublease Income IncreaseDecreaseInDeferredSubleaseIncome	0	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-799000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1033000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	484000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	14129000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52395000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34896000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	17990000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	40585000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	60000000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12038000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41374000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	105000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30077000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81959000	usd
CY2023	snti	Proceeds From Merger And Related Pipe Financing Net Of Transaction Costs ProceedsFromMergerAndRelatedPIPEFinancingNetOfTransactionCosts	0	usd
CY2022	snti	Proceeds From Merger And Related Pipe Financing Net Of Transaction Costs ProceedsFromMergerAndRelatedPIPEFinancingNetOfTransactionCosts	111976000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	521000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	512000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	728000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	375000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	151000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5175000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	108000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	779000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118551000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21539000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1696000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60987000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39448000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60987000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35926000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57621000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3522000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3366000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39448000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60987000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8153000	usd
CY2023	snti	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	300100000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173300000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71100000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58200000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	35900000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	98600000	usd
CY2023	snti	Number Of Business Activities NumberOfBusinessActivities	1	businessactivitiy
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	reportablesegment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of GeneFab Option, the valuation of GeneFab Economic Share, the valuation of the GeneFab Note Receivable, the discount rate used to discount future cash flows for the impairment of long-lived assets, and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents, and short-term investments that are maintained in checking and money market accounts at one financial institution, which at times, may exceed federally insured limits. The Company’s short-term investments, if any, are limited to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, and places restrictions on maturities and concentration by type and issuer. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company has prepaid future manufacturing and research services of $14.8 million under the development and manufacturing services agreement entered into with GeneFab, a related party. The Company also has a receivable from GeneFab under the framework agreement with a fair value of $17.2 million, subject to satisfaction of certain conditions. The prepaid expense and receivable balances from GeneFab potentially subject the Company to a significant concentration of credit risk if the Company is unable to realize these balances. Refer to Note 4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneFab Transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details of the GeneFab transaction.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35926000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57621000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3522000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3366000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39448000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60987000	usd
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	P20D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	P30D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Threshold Of Years For Change Of Control ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl	P3Y
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5060000	shares
CY2022Q2	snti	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	23163614	shares
CY2022Q2	snti	Early Exercised Shares Subject To Repurchase EarlyExercisedSharesSubjectToRepurchase	288807	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43368270	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	19517988	shares
CY2022Q2	snti	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	140700000	usd
CY2022Q2	snti	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	23500000	usd
CY2022Q2	snti	Reverse Recapitalization Transaction Costs Incurred By Company ReverseRecapitalizationTransactionCostsIncurredByCompany	4800000	usd
CY2022	snti	Reverse Recapitalization Accrued Transaction Costs ReverseRecapitalizationAccruedTransactionCosts	0	usd
CY2023Q4	snti	Cash Cash Equivalents Restricted Cash And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost	39448000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	snti	Cash Cash Equivalents Restricted Cash And Debt Securities Available For Sale Fair Value CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue	39448000	usd
CY2022Q4	snti	Cash Cash Equivalents Restricted Cash And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost	101928000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	usd
CY2022Q4	snti	Cash Cash Equivalents Restricted Cash And Debt Securities Available For Sale Fair Value CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue	101929000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2546000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1871000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	42000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1209000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	195000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	101000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31520000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	54316000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6182000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2955000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25338000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51361000	usd
CY2023	us-gaap	Depreciation Depreciation	3400000	usd
CY2022	us-gaap	Depreciation Depreciation	1400000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7342000	usd
CY2023Q4	snti	Accrued Professional Fees Other Current AccruedProfessionalFeesOtherCurrent	3555000	usd
CY2022Q4	snti	Accrued Professional Fees Other Current AccruedProfessionalFeesOtherCurrent	3496000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2363000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1709000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5927000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12576000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	5277000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5300000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	73000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	81000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1138000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	730000	usd
CY2023	us-gaap	Lease Cost LeaseCost	6488000	usd
CY2022	us-gaap	Lease Cost LeaseCost	6111000	usd
CY2023	snti	Operating Lease Proceeds Payments OperatingLeaseProceedsPayments	-2922000	usd
CY2022	snti	Operating Lease Proceeds Payments OperatingLeaseProceedsPayments	11363000	usd
CY2023	snti	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Adjustments RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfAdjustments	-5000	usd
CY2022	snti	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Net Of Adjustments RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityNetOfAdjustments	231000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.092
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	163834000	usd
CY2022Q2	snti	Temporary Equity Conversion Ratio TemporaryEquityConversionRatio	1
CY2023Q4	snti	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2023	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7254000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7478000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7712000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5769000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4855000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	19529000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	52597000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15028000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	37569000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	4345000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	4476000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	4610000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	4748000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	4891000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	18295000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	41365000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	19517990	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	44832169	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24186271	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	P30D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Threshold Of Years For Change Of Control ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl	P3Y
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Fair Value ReverseRecapitalizationContingentConsiderationFairValue	9800000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9700000	usd
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-200000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9500000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	800000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1000000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4191426	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.18
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2914196	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.60
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	869943	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.33
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6235679	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.42
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2270135	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.47
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5200000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8000000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11692000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15562000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33566000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25249000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	10146000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5131000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9237000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6053000	usd
CY2023Q4	snti	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6005000	usd
CY2022Q4	snti	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7789000	usd
CY2023Q4	snti	Deferred Tax Assets Share Based Compensation DeferredTaxAssetsShareBasedCompensation	4785000	usd
CY2022Q4	snti	Deferred Tax Assets Share Based Compensation DeferredTaxAssetsShareBasedCompensation	683000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	724000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	756000	usd
CY2023Q4	snti	Deferred Tax Assets Fair Value Adjustment Related Party DeferredTaxAssetsFairValueAdjustmentRelatedParty	346000	usd
CY2022Q4	snti	Deferred Tax Assets Fair Value Adjustment Related Party DeferredTaxAssetsFairValueAdjustmentRelatedParty	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	259000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64809000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45920000	usd
CY2023Q4	snti	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	1548000	usd
CY2022Q4	snti	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3869000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2008000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3556000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3869000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61253000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42051000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19200000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12300000	usd
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-8545000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-71058000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0330
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0086
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0093
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0337
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0121
CY2023	snti	Effective Income Tax Rate Reconciliation Fair Value Of Preferred Stock Tranche Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfPreferredStockTrancheLiabilityPercent	0
CY2022	snti	Effective Income Tax Rate Reconciliation Fair Value Of Preferred Stock Tranche Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfPreferredStockTrancheLiabilityPercent	0
CY2023	snti	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Earnout Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfContingentEarnoutLiabilityPercent	0.0104
CY2022	snti	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Earnout Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfContingentEarnoutLiabilityPercent	0.0341
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2784
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2456
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1643000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1252000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	243000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	109000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	676000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	500000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2076000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1643000	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-83406000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-49665000	usd
CY2023Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	12348000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44372223	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44372223	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26110785	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26110785	shares
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.88
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.88
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.90
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.90
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.28
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.33
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.33
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.60
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33496524	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12429123	shares
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46000000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P11Y
CY2023	snti	Collaborative Arrangement Rights And Obligations Contractual Annual Payments CollaborativeArrangementRightsAndObligationsContractualAnnualPayments	200000	usd
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2023Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	6	board_seat
CY2022Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	board_seat
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	San Francisco, CA,
CY2023	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001854270-24-000029-index-headers.html	Edgar Link	pending
0001854270-24-000029-index.html	Edgar Link	pending
0001854270-24-000029.txt	Edgar Link	pending
0001854270-24-000029-xbrl.zip	Edgar Link	pending
a2023123110kex1041.htm	Edgar Link	pending
a2023123110kex231.htm	Edgar Link	pending
a2023123110kex311.htm	Edgar Link	pending
a2023123110kex312.htm	Edgar Link	pending
a2023123110kex321.htm	Edgar Link	pending
a2023123110kex322.htm	Edgar Link	pending
a2023123110kex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snti-20231231.htm	Edgar Link	pending
snti-20231231.xsd	Edgar Link	pending
snti-20231231_g1.jpg	Edgar Link	pending
snti-20231231_g10.jpg	Edgar Link	pending
snti-20231231_g11.jpg	Edgar Link	pending
snti-20231231_g12.jpg	Edgar Link	pending
snti-20231231_g13.jpg	Edgar Link	pending
snti-20231231_g14.jpg	Edgar Link	pending
snti-20231231_g15.jpg	Edgar Link	pending
snti-20231231_g16.jpg	Edgar Link	pending
snti-20231231_g17.jpg	Edgar Link	pending
snti-20231231_g18.jpg	Edgar Link	pending
snti-20231231_g19.jpg	Edgar Link	pending
snti-20231231_g2.jpg	Edgar Link	pending
snti-20231231_g20.jpg	Edgar Link	pending
snti-20231231_g21.jpg	Edgar Link	pending
snti-20231231_g3.jpg	Edgar Link	pending
snti-20231231_g4.jpg	Edgar Link	pending
snti-20231231_g5.jpg	Edgar Link	pending
snti-20231231_g6.jpg	Edgar Link	pending
snti-20231231_g7.jpg	Edgar Link	pending
snti-20231231_g8.jpg	Edgar Link	pending
snti-20231231_g9.jpg	Edgar Link	pending
snti-20231231_pre.xml	Edgar Link	unprocessable
snti-20231231_htm.xml	Edgar Link	completed
snti-20231231_def.xml	Edgar Link	unprocessable
snti-20231231_lab.xml	Edgar Link	unprocessable
snti-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNTI
Senti Biosciences, Inc. Stock $snti

2024 Q1 Form 10-K Financial Statement

#000185427024000029 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNTI Senti Biosciences, Inc. Stock $snti

2024 Q1 Form 10-K Financial Statement

#000185427024000029 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNTI
Senti Biosciences, Inc. Stock $snti